• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease - who and how?

作者信息

Teng Margaret Lp, Tan Darren Jun Hao, Ng Cheng Han, Huang Daniel Q

机构信息

Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore.

Yong Loo Lin School of Medicine, National University of Singapore, Singapore.

出版信息

Clin Mol Hepatol. 2023 Apr;29(2):404-407. doi: 10.3350/cmh.2023.0069. Epub 2023 Mar 14.

DOI:10.3350/cmh.2023.0069
PMID:36916168
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10121276/
Abstract
摘要

相似文献

1
Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease - who and how?非酒精性脂肪性肝病中的肝细胞癌监测——对象及方法？
Clin Mol Hepatol. 2023 Apr;29(2):404-407. doi: 10.3350/cmh.2023.0069. Epub 2023 Mar 14.
2
Reply to: "Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease".回复：“多基因风险评分：非酒精性脂肪性肝病患者肝细胞癌的一种有前景的预测指标”
J Hepatol. 2021 Jun;74(6):1494-1496. doi: 10.1016/j.jhep.2021.02.030. Epub 2021 Mar 5.
3
Hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis.非酒精性脂肪性肝炎相关肝硬化外的肝细胞癌。
World J Gastroenterol. 2023 Jan 14;29(2):343-356. doi: 10.3748/wjg.v29.i2.343.
4
Nonalcoholic steatohepatitis and hepatocellular carcinoma: Brazilian survey.非酒精性脂肪性肝炎与肝细胞癌：巴西调查
Clinics (Sao Paulo). 2016 May;71(5):281-4. doi: 10.6061/clinics/2016(05)07.
5
Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.非酒精性脂肪性肝病相关肝细胞癌的临床特征：一项人体研究综述
Clin J Gastroenterol. 2015 Feb;8(1):1-9. doi: 10.1007/s12328-014-0548-5. Epub 2015 Jan 10.
6
[Non-alcoholic fatty liver disease; a full-bodied epidemic].[非酒精性脂肪性肝病；一场全面爆发的流行病]
Ned Tijdschr Geneeskd. 2020 Feb 27;164:D4096.
7
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.非酒精性脂肪性肝病/非酒精性脂肪性肝炎与肝细胞癌。
Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.
8
Non-alcoholic fatty liver disease: Definition and subtypes.非酒精性脂肪性肝病：定义和亚型。
Clin Mol Hepatol. 2023 Feb;29(suppl):S5-S16. doi: 10.3350/cmh.2022.0424. Epub 2022 Dec 28.
9
Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.肝癌：与肥胖、脂肪肝和肝硬化的关联。
Annu Rev Med. 2016;67:103-17. doi: 10.1146/annurev-med-090514-013832. Epub 2015 Oct 14.
10
Incidence of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病中肝细胞癌的发病率
Gastroenterology. 2022 May;162(6):1772-1774. doi: 10.1053/j.gastro.2022.01.037. Epub 2022 Feb 1.

引用本文的文献

1
Hepatocyte-specific angiotensinogen deficiency inhibits Western diet-induced liver steatosis with suppression of cell division in mice.肝细胞特异性血管紧张素原缺乏通过抑制小鼠细胞分裂来抑制西方饮食诱导的肝脏脂肪变性。
Glob Transl Med. 2025;4(2):71-85. doi: 10.36922/gtm.6027. Epub 2025 Apr 10.
2
The gut microbiota-mediated ferroptosis pathway: a key mechanism of ginsenoside Rd against metabolism-associated fatty liver disease.肠道微生物群介导的铁死亡途径：人参皂苷Rd抗代谢相关脂肪性肝病的关键机制
Chin Med. 2025 Jun 10;20(1):83. doi: 10.1186/s13020-025-01121-1.
3
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review.代谢功能障碍相关脂肪性肝病（MASLD）：最新综述
J Obes Metab Syndr. 2023 Sep 30;32(3):197-213. doi: 10.7570/jomes23052. Epub 2023 Sep 13.
4
Hepatocellular carcinoma surveillance - utilization, barriers and the impact of changing aetiology.肝细胞癌监测——利用、障碍以及病因变化的影响。
Nat Rev Gastroenterol Hepatol. 2023 Dec;20(12):797-809. doi: 10.1038/s41575-023-00818-8. Epub 2023 Aug 3.

本文引用的文献

1
Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future.非酒精性脂肪性肝病肝纤维化的无创性影像学生物标志物：现状与展望。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S136-S149. doi: 10.3350/cmh.2022.0436. Epub 2022 Dec 12.
2
Identification of high-risk subjects in nonalcoholic fatty liver disease.非酒精性脂肪性肝病高危人群的识别。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S196-S206. doi: 10.3350/cmh.2022.0431. Epub 2022 Dec 5.
3
Current Challenges and Future Direction in Surveillance for Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病患者肝细胞癌监测的当前挑战与未来方向
Semin Liver Dis. 2023 Feb;43(1):89-99. doi: 10.1055/a-1957-8540. Epub 2022 Oct 10.
4
Hepatocellular carcinoma surveillance in patients with non-alcoholic fatty liver disease.非酒精性脂肪性肝病患者的肝细胞癌监测。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S207-S219. doi: 10.3350/cmh.2022.0247. Epub 2022 Sep 14.
5
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.2010 年至 2019 年全球肝癌流行病学变化：NASH 是肝癌增长最快的病因。
Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003. Epub 2022 Jun 3.
6
Mortality Outcomes by Fibrosis Stage in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis.非酒精性脂肪性肝病纤维化分期的死亡率结局：系统评价和荟萃分析。
Clin Gastroenterol Hepatol. 2023 Apr;21(4):931-939.e5. doi: 10.1016/j.cgh.2022.04.014. Epub 2022 May 2.
7
Liver resection versus liver transplantation for hepatocellular carcinoma within Milan criteria: a meta-analysis of 18,421 patients.米兰标准内肝细胞癌的肝切除术与肝移植术对比：18421例患者的荟萃分析
Hepatobiliary Surg Nutr. 2022 Feb;11(1):78-93. doi: 10.21037/hbsn-21-350.
8
Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis.非酒精性脂肪性肝病相关肝细胞癌的临床特征、监测、治疗分配和结局：系统评价和荟萃分析。
Lancet Oncol. 2022 Apr;23(4):521-530. doi: 10.1016/S1470-2045(22)00078-X. Epub 2022 Mar 4.
9
Global and regional long-term survival following resection for HCC in the recent decade: A meta-analysis of 110 studies.近十年肝癌切除术后的全球和区域长期生存：110 项研究的荟萃分析。
Hepatol Commun. 2022 Jul;6(7):1813-1826. doi: 10.1002/hep4.1923. Epub 2022 Mar 2.
10
HCC surveillance improves early detection, curative treatment receipt, and survival in patients with cirrhosis: A meta-analysis.HCC 监测可提高肝硬化患者的早期检测、根治性治疗的获得和生存率：一项荟萃分析。
J Hepatol. 2022 Jul;77(1):128-139. doi: 10.1016/j.jhep.2022.01.023. Epub 2022 Feb 6.